A new study links a well-known cell communication pathway called Notch to pilocytic astrocytoma (PA), one of the more common brain tumors found in children.
The molecular mail sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study presented at ASH. The findings may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma.
Molecular tests are poised to become a part of the treatment guidelines for prostate cancer. These tests provide information that extends beyond just identifying the type of cancer a patient has; they can also help narrow down treatment options to those that offer the best outcomes for patients.
A new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network has identified markers of aggressive tumors, which could allow for improved targeted therapy.
Cytokine therapy enhances the activity of natural killer (NK) cells against tumors that lack the cell surface protein known as MHC class I, according to new research.
Evidence now suggests that human colon cells may become cancerous when they lose the ability to produce a specific hormone. For patients with colon cancer, replacing the hormone guanylin might prevent cancer development.
Blocking STAT3 in cells of the immune system actually leads to increased antitumor immunity, according to new research.
JAK inhibitors have been found to halt tumor growth in colorectal cancer with a certain genetic mutation, according to a new study.
Scientists have developed a tool to distinguish each breast cancer subtype, research that could improve treatments and targeting of treatments for the disease.
An international scientific collaboration has revealed clues about genetic alterations that may contribute to a rare form of kidney cancer, providing new insights not only into this rare cancer but other types as well.
All types of cancers appear to share a telltale signature of widespread changes to the epigenome.
Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.
Researchers have identified a gene that contributes to the development of several childhood cancers, research that could lead to new strategies for targeting certain childhood cancers at a molecular level.
A protein present at high levels in more than half of all human cancers drives cell growth by blocking the expression of just a handful of genes involved in DNA packaging and cell death.
Brain tumors fly under the radar of the body's defense forces by coating their cells with extra amounts of a specific protein, according to new research.
The PALB2 gene is potentially one of the most important genes associated with breast cancer after the BRCA1/2 genes.
New research suggests that cancer would be more accurately diagnosed in 1 of every 10 patients if their tumors were defined by cellular and molecular criteria rather than by the tissues in which they originated, and that this information, in turn, could lead to more appropriate treatments.
In a massive effort to catalog the molecular causes of stomach cancer, scientists have identified four subtypes of tumors based on shared mutations and other molecular abnormalities. They say the new classification promises to advance clinical research to develop improved therapies for the third-leading cancer killer worldwide.
In an analysis of small molecules called metabolites, a research team identified an enzyme key to applying the brakes on tumor growth.
The spreading of a cancerous tumor from one part of the body to another may occur through pure chance rather than through key genetic mutations, a new study has shown.
Scientists have identified a gene responsible for stopping the movement of cancer from the lungs to other parts of the body, indicating a new way to fight one of the world's deadliest cancers.
A research team has discovered how two genes cause colorectal cancer cells to become resistant to treatments used against the disease.
A new study has identified three genetic changes in East Asian women linked to an increased risk of breast cancer.
For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that does not require extensive therapy.
Researchers have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.
A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy.
The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.
Circulating tumor cells captured with a microchip-based device can be cultured to establish cell lines for genetic analysis and drug testing.
Researchers from the University of Illinois at Chicago have discovered how cholesterol activates a cellular signaling pathway linked to cancer development. Previous studies have associated high cholesterol with certain cancers. But in this study, the researchers focused on the signaling pathways used to direct cell function.
- Risk of thyroid cancer increases after a breast cancer diagnosis
- Childhood leukemia study reveals disease subtypes and new treatment options
- Counseling cancer patients on effective nutritional practices
- Chemotherapy before breast cancer surgery increases likelihood of breast-preserving procedure
- Effective management of dietary cholesterol may prevent metastasis in patients with prostate cancer
- Treatment guidelines for pediatric Hodgkin lymphoma issued by the International Lymphoma Radiation Oncology Group (ILROG)
- Joint statement offers new recommendations for treating cardiovascular conditions
- Physicians who review patients' meds more likely to achieve health goals
- Patients expect more information regarding radiation-related tests
- Prevalence of childhood cancer survivors increasing
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|